Title:Yuflyma, A High Concentration and Citrate-free Adalimumab Biosimilar,
Received FDA Approval for Treating Different Forms of Inflammato ry
Diseases
Volume: 22
Issue: 4
Author(s): Vinod Kumar Rajana, Sudha Madhavi Penumaka, Cevella Saritha, Velayutham Ravichandiran and Debabrata Mandal*
Affiliation:
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, 844102, India
Keywords:
Adalimumab biosimilar, yuflyma, TNFα, TNF receptor, rheumatoid arthritis, inflammation.